NEW paper highlights how Most Favored Nation (MFN) pricing will hurt American innovation and, with it, patients in need. A model of an MFN-style price-setting policy found it would have resulted in 167 to 342 fewer new approved drugs over an 18-year timeframe. Learn more about why MFN ultimately fails patients awaiting the next treatment or cure: cato.org/regulation/summer-2…